RT Journal Article
SR Electronic
T1 LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.09.30.318972
DO 10.1101/2020.09.30.318972
A1 Bryan E. Jones
A1 Patricia L. Brown-Augsburger
A1 Kizzmekia S. Corbett
A1 Kathryn Westendorf
A1 Julian Davies
A1 Thomas P. Cujec
A1 Christopher M. Wiethoff
A1 Jamie L. Blackbourne
A1 Beverly A. Heinz
A1 Denisa Foster
A1 Richard E. Higgs
A1 Deepa Balasubramaniam
A1 Lingshu Wang
A1 Roza Bidshahri
A1 Lucas Kraft
A1 Yuri Hwang
A1 Stefanie Žentelis
A1 Kevin R. Jepson
A1 Rodrigo Goya
A1 Maia A. Smith
A1 David W. Collins
A1 Samuel J. Hinshaw
A1 Sean A. Tycho
A1 Davide Pellacani
A1 Ping Xiang
A1 Krithika Muthuraman
A1 Solmaz Sobhanifar
A1 Marissa H. Piper
A1 Franz J. Triana
A1 Jorg Hendle
A1 Anna Pustilnik
A1 Andrew C. Adams
A1 Shawn J. Berens
A1 Ralph S. Baric
A1 David R. Martinez
A1 Robert W. Cross
A1 Thomas W. Geisbert
A1 Viktoriya Borisevich
A1 Olubukola Abiona
A1 Hayley M. Belli
A1 Maren de Vries
A1 Adil Mohamed
A1 Meike Dittmann
A1 Marie Samanovic
A1 Mark J. Mulligan
A1 Jory A. Goldsmith
A1 Ching-Lin Hsieh
A1 Nicole V. Johnson
A1 Daniel Wrapp
A1 Jason S. McLellan
A1 Bryan C. Barnhart
A1 Barney S. Graham
A1 John R. Mascola
A1 Carl L. Hansen
A1 Ester Falconer
YR 2020
UL http://biorxiv.org/content/early/2020/10/01/2020.09.30.318972.abstract
AB SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection.One Sentence Summary LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.Competing Interest StatementM.J.M. has research grant funding from NIH/NIAID, Pfizer, and Sanofi; and personal fees from Meissa Vaccines, Inc. B.E.J., P.LB., J.D., T.P.C., C.M.W., J.L.B., B.A.H., R.E.H., D.B., D.F., M.H.P., F.J.T., J.H., A.P., A.C.A. and S.J.B. are employees and stockholders of Eli Lilly and Company. K.W., R.B., L.K., S.J.H., S.S., B.C.B, and E.F. are employees of AbCellera Biologics Inc. C.L.H., R.G., D.P., P.X., Y.H., R.B., K.R.J. M.A.S., S.Z., D.W.C., and S.A.T. are employees and stockholders of AbCellera Biologics Inc.. K.M. is a former employee and stockholder of AbCellera Biologics Inc. M.D. received a contract from Eli Lilly and Company to support the studies reported herein. Authors from AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (K.S.C., B.S.G., and J.R.M.), and Eli Lilly and Company are inventors on patent applications related to the work described here. R.S.B., D.R.M., R.W.C., T.W.G, V.B., O.A., L.W., H.M.B., M.D.V., A.D., M.S., J.A.G., C.L.H., N.V.J., J.S.M., and D.W. declare no competing interests.